Drug Profile
Panobinostat - Biodexa Pharmaceuticals
Alternative Names: BDX-110; MTX 110Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals
- Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Diffuse intrinsic pontine glioma
- Phase I Glioblastoma
- Phase 0 Medulloblastoma
Most Recent Events
- 19 Apr 2024 Midatech announces intention to file IND application to FDA for a phase II clinical trial in Diffuse intrinsic pontine glioma in end of the 2024
- 23 Feb 2024 Adverse events and efficacy data from a phase I trial in Diffuse intrinsic pontine glioma released by Biodexa Pharmaceuticals
- 23 Jan 2024 Interim efficacy data from a phase I in Glioblastoma released by Biodexa Pharmaceuticals